Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Platelet miRNA Biosignature Discriminates between Dementia with Lewy Bodies and Alzheimer's Disease

  • Gámez-Valero, Ana|||0000-0002-9530-2751
  • Campdelacreu, Jaume|||0000-0001-9196-7601
  • Vilas Rolán, Dolores|||0000-0003-3084-053X
  • Ispierto, Lourdes
  • Gascon Bayarri, Jordi|||0000-0002-9422-937X
  • Reñé, Ramón
  • Álvarez, Ramiro|||0000-0002-8053-7232
  • Armengol, Maria P.
  • Borràs i Serres, Francesc Enric|||0000-0003-4038-1912
  • Beyer, Katrin|||0000-0001-8905-1514
Dementia with Lewy bodies (DLB) is one of the most common causes of degenerative dementia, after Alzheimer's disease (AD), and presents pathological and clinical overlap with both AD and Parkinson's disease (PD). Consequently, only one in three DLB cases is diagnosed correctly. Platelets, previously related to neurodegeneration, contain microRNAs (miRNAs) whose analysis may provide disease biomarkers. Here, we profiled the whole platelet miRNA transcriptome from DLB patients and healthy controls. Differentially expressed miRNAs were further validated in three consecutive studies from 2017 to 2019 enrolling 162 individuals, including DLB, AD, and PD patients, and healthy controls. Results comprised a seven-miRNA biosignature, showing the highest diagnostic potential for the differentiation between DLB and AD. Additionally, compared to controls, two miRNAs were down-regulated in DLB, four miRNAs were up-regulated in AD, and two miRNAs were down-regulated in PD. Predictive target analysis identified three disease-specific clusters of pathways as a result of platelet-miRNA deregulation. Our cross-sectional study assesses the identification of a novel, highly specific and sensitive platelet-associated miRNA-based biosignature, which distinguishes DLB from AD.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Expression Levels of an Alpha-Synuclein Transcript in Blood May Distinguish between Early Dementia with Lewy Bodies and Parkinson's Disease

  • Marsal-García, Laura|||0000-0002-6337-1656
  • Campdelacreu, Jaume|||0000-0001-9196-7601
  • Vilas Rolán, Dolores|||0000-0003-3084-053X
  • Ispierto, Lourdes
  • Gascon Bayarri, Jordi|||0000-0002-9422-937X
  • Reñé, Ramón
  • Álvarez, Ramiro|||0000-0002-8053-7232
  • Beyer, Katrin|||0000-0001-8905-1514
  • Urbizu, Aintzane|||0000-0001-8458-1209
  • Arnaldo, Laura|||0000-0003-1654-0573
Lewy body diseases (LBD) including dementia with Lewy bodies (DLB) and Parkinson disease (PD) are characterized by alpha-synuclein pathology. DLB is difficult to diagnose and peripheral biomarkers are urgently needed. Therefore, we analyzed the expression of five alpha-synuclein gene (SNCA) transcripts, SNCAtv1, SNCAtv2, SNCAtv3, SNCA126, and SNCA112, in 45 LBD and control temporal cortex samples and in the blood of 72 DLB, 59 PD, and 54 control subjects. The results revealed overexpression of SNCAtv1 and SNCA112 in DLB, and SNCAtv2 in PD temporal cortices. In DLB blood, diminution of all SNCA transcripts was observed. SNCAtv1 and SNCAtv2 were diminished in PD with disease onset before 70 years. SNCAtv3, driven by its own promoter, showed opposite expression in early DLB and PD, suggesting that its amount may be an early, DLB specific biomarker. Correlation between blood transcript levels and disease duration was positive in DLB and negative in PD, possibly reflecting differences in brain alpha-synuclein aggregation rates associated with differences in disease courses. In conclusion, SNCA transcripts showed a disease-specific increase in the brain and were diminished in blood of LBD patients. SNCAtv3 expression was decreased in early DLB and increased in early PD and could be a biomarker for early DLB diagnosis.